louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01126788: Comparative Physiologic Technology Study
Official title: Comparative Physiologic Technology Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peripheral Arterial Disease
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2010-05-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients referred to the MGH Vascular Labs for diagnostic testing for PAD

Brief summary: This study is designed to test two hypotheses:

1. The PADnet+ testing system produces clinically equivalent results as the Parks Flo-Lab testing system in a group of patients referred for evaluation of PAD of the limbs when performed by a Registered Vascular Technologist (RVT).
2. The PADnet+ testing system produces clinically equivalent results when the testing is repeated on the above patients and performed by staff specifically trained on the use of the PADnet+ system but are not vascular technologists nor hold the RVT certification.


Eligibility criteria: Inclusion Criteria:

* All patients referred to the MGH Vascular Labs for diagnostic testing for PAD

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachsetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Glenn LaMuraglia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06915688: A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
Official title: Comparison of Clinical Cure Rate of Doxycycline and Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: COPD
Keywords: COPD
Lead sponsor: Lahore General Hospital
Sponsor class: OTHER_GOV
First posted: 2025-04-08
Enrollment: 188
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will include patients with chronic obstructive pulmonary disease (COPD) who present with an acute exacerbation. Participants will be randomly assigned to receive either doxycycline or levofloxacin for 5 days. The aim is to compare how effective each antibiotic is in improving symptoms after 2 days of treatment.

Detailed description: This randomized controlled trial will evaluate the effectiveness of two antibiotics-doxycycline (a tetracycline) and levofloxacin (a fluoroquinolone)-in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Participants will be assigned to one of the two treatment groups and will receive either doxycycline 100 mg twice daily or levofloxacin 500 mg once daily for 5 days. The primary outcome is clinical cure. This will be evaluated 2 days after completion of antibiotic therapy, based on symptom resolution and laboratory markers.

Eligibility criteria: Inclusion Criteria:

* diagnosed cases of COPD Exacerbation of COPD Able to provide Written consent No anti biotic taken with in past 4 weeks

Exclusion Criteria:

* hypersensitivity to any drugs Pneumonia evidence on xray/ hrct chest Any other pulmonary condition e.g asthma Pregnancy/breast feeding Taking treatment for other active infections

Primary outcomes:
measure: Clinical Cure Rate
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: General hospital
Study officials:
References:
Clinical trial NCT06901388: Peri-implant Disease Perception Before and After Non-Surgical Peri-implant Therapy
Official title: Peri-implant Disease Perception Before and After Non-Surgical Peri-implant Therapy: A Pre-post Quasi-Experimental Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Peri-implant Mucositis
Peri-Implantitis
Keywords: Oral Health Impact Profile 14
Brief-Illness Perception Questionnaire
Non-surgical peri-implant therapy
Lead sponsor: University of Siena
Sponsor class: OTHER
First posted: 2025-03-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The present pre-post quasi-experimental study assessed changes in peri-implant disease perception and oral health-related quality of life following non-surgical peri-implant therapy. Using validated psychometric tools, including the Brief Illness Perception Questionnaire (Brief-IPQ) and the Oral Health Impact Profile-14 (OHIP-14), the study evaluates patients at baseline and three months after therapy. The study builds upon prior cross-sectional findings highlighting the low perception of peri-implant diseases and aims to determine whether non-surgical treatment improves patients' psychological awareness and perceived impact of their condition.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 to 80 years
* Diagnosis of peri-implant disease requiring non-surgical therapy
* Presence of at least one dental implant loaded for a minimum of one year
* History of periodontitis
* Good general health
* Ability to provide written informed consen

Exclusion Criteria:

* Pregnant or lactating individuals
* Inability to perform basic oral hygiene procedures
* Inability to understand or complete study questionnaires

Primary outcomes:
measure: Change in illness perception (Brief-IPQ total score)
timeFrame: Baseline and 3 months from baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Siena
country: Italy
facility: AOUS
Study officials:
References:
Clinical trial NCT05926388: Video-Assisted Instruction in Type 2 Diabetes Patients
Official title: The Effect of Video-Assisted Instruction in Type 2 Diabetes Patients' Insulin Self-Management and Insulin Administration Skills
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Education, Patient
Keywords: self-management
Type 2 diabetes mellitus
video-assisted instruction
Lead sponsor: Izmir Bakircay University
Sponsor class: OTHER
First posted: 2023-07-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of the study of examine the effect of video-assisted instruction on Type 2 diabetes patients' insulin treatment self-management and insulin administration skills. The research will be conducted as a single group pre-test post-test quasi-experimental study. The sample of the study will be consisted of 50 patients with Type 2 Diabetes. Before the training, the patients will be self-injected a dose of insulin. After giving verbal training, the patients will watch a video recording of insulin treatment and administration. The author will be evaluated the patients' insulin treatment self-management and insulin administration skills after the training.

Detailed description: The aim of the study of examine the effect of video-assisted instruction on Type 2 diabetes patients' insulin treatment self-management and insulin administration skills. The research will be conducted as a single group pre-test post-test quasi-experimental study. The sample of the study will be consisted of 50 patients with Type 2 Diabetes. Before the training, the patients will be self-injected a dose of insulin. After giving verbal training, the patients will watch a video recording of insulin treatment and administration. The author will be evaluated the patients' insulin treatment self-management and insulin administration skills after the training.

Eligibility criteria: Inclusion Criteria

* 18-65 years
* No hearing or communication problems
* Self-injecting insulin

Exclusion Criteria

* Health care professionals
* Chronic complications
* Pregnant

Primary outcomes:
measure: Insulin Treatment Self-Management Scale 1 (Questionnaire)
timeFrame: Seven days after the training
measure: Insulin Treatment Self-Management Scale 2 (Questionnaire)
timeFrame: Five weeks after the training
measure: Insulin Administration Observation Form 1
timeFrame: Seven days after the training
measure: Insulin Administration Observation Form 2
timeFrame: Five weeks after the training
Secondary outcomes:
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: izmir Bakircay University
state: Menemen
Study officials:
References:
Clinical trial NCT00578188: Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract
Official title: Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Chlamydia Infection
Keywords: Adolescent Health
Sexually transmitted infection
Women's Health
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2007-12-21
Enrollment: 0
Sex: FEMALE
Minimum age (years): 11
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 11-19 year old females from the Arkansas Children's Hospital Adolescent Center

Brief summary: The purpose of this study is to determine if Chlamydial infections persist in the rectum of females who have had a sexually transmitted infection of Chlamydia.


Eligibility criteria: Inclusion Criteria:

* 11-19 years old
* Female
* Diagnosis of Chlamydia on enrollment visit
* Invitation to participate control group

Exclusion Criteria:

* Age out of range
* Negative Chlamydia screen (unless qualifies for control group)
* Unable to provide needed samples

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Hospital
state: Arkansas
Study officials:
affiliation: Arkansas Children's Hospital Research Institute
name: Amy M Scurlock, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Centers for Disease Control and Prevention (CDC). Chlamydia trachomatis genital infections--United States, 1995. MMWR Morb Mortal Wkly Rep. 1997 Mar 7;46(9):193-8.
citation: Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis. 2000 Sep;182(3):909-16. doi: 10.1086/315778. Epub 2000 Aug 17.
citation: Jones RB, Rabinovitch RA, Katz BP, Batteiger BE, Quinn TS, Terho P, Lapworth MA. Chlamydia trachomatis in the pharynx and rectum of heterosexual patients at risk for genital infection. Ann Intern Med. 1985 Jun;102(6):757-62. doi: 10.7326/0003-4819-102-6-757.
citation: Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun. 1997 Jun;65(6):2145-52. doi: 10.1128/iai.65.6.2145-2152.1997.
citation: Igietseme JU, Portis JL, Perry LL. Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae. Infect Immun. 2001 Mar;69(3):1832-40. doi: 10.1128/IAI.69.3.1832-1840.2001.
Clinical trial NCT06556888: Observatory of Immunological Thrombopenic Purpura in the Brest Region
Official title: Observatory of Immunological Thrombopenic Purpura in the Brest Region: Descriptive and Comparative Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Immune Thrombocytopenia
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2024-08-16
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with ITP diagnosed, treated or followed at UHB

Brief summary: Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.

Detailed description: Creation of a global clinical and biological database for all patients diagnosed, treated and followed for ITP in the University Hospital of Brest.

UHB is the regional reference center (competence center) on hemorrhagic diseases.

Dr Pan-Petesch, who is responsible of the local competence center, is affiliated to the national sector of auto-immune cytopenias CERECAI-MARIH).

Eligibility criteria: Inclusion Criteria:

* Patients with ITP agree to participate

Exclusion Criteria:

* Other thrombocythopenia other than ITP
* Patients Under guardianship
* Patients without national social security

Primary outcomes:
measure: Description chronicity
timeFrame: 1 year
measure: Description treatment responses
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Hematology Department - Institute of Oncology and Hematology, University Hospital of Brest
state: Bretagne
Study officials:
affiliation: UHB
name: Brigitte Pan-Petesch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02394288: Perioperative Cardiac Troponin Levels in Healthy Adults
Official title: Perioperative High-sensitivity Cardiac Troponin Levels in Healthy Adults Undergoing Elective Trauma Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Extremity Orthopedic Surgery
Keywords: Cardiac Troponin
Perioperative Period
surgery
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: Washington University School of Medicine
First posted: 2015-03-20
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing extremity surgery without history of cardiovascular disease

Brief summary: This study will determine the extent of high-sensitivity cardiac troponin (hs-cTn) release in patients without cardiac risk factors undergoing extremity orthopedic surgery. This study will provide important evidence on how to interpret postoperative cardiac troponin elevations.


Eligibility criteria: Inclusion Criteria:

* Age 18-35 years
* Extremity orthopedic or trauma surgery: leg, hip, arm, shoulder.
* Planned overnight hospital admission
* No cardiac risk factors (Lee's Revised Cardiac Risk Index Class 1)
* American Society of Anesthesiologists (ASA) physical status I-II

Exclusion Criteria:

* Any history or symptoms of cardiac disease
* Kidney or liver disease
* Recent or current trauma to the trunk or head
* Persons with increased vulnerability (e.g. cognitive limitations, prisoners,...)
* Pregnancy

Primary outcomes:
measure: Perioperative change of high-sensitivity cardiac troponin plasma level
timeFrame: 24 hours preoperatively to postoperative day (POD) 1
Secondary outcomes:
measure: Peak high-sensitivity cardiac troponin plasma level
timeFrame: 24 hours preoperatively to POD 1
measure: Incidence rate of high-sensitivity cardiac troponin plasma level elevation
timeFrame: 24 hours preoperatively to POD 1
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Division of General Anaesthesia and Intensive Care Medicine, Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Andreas Duma, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Duma A, Wagner C, Titz M, Maleczek M, Hupfl M, Weihs VB, Samaha E, Herkner H, Szekeres T, Mittlboeck M, Scott MG, Jaffe AS, Nagele P. High-sensitivity cardiac troponin T in young, healthy adults undergoing non-cardiac surgery. Br J Anaesth. 2018 Feb;120(2):291-298. doi: 10.1016/j.bja.2017.09.001. Epub 2017 Dec 5.
Clinical trial NCT05379088: Activity Level Monitoring Study
Official title: Activity Level Monitoring Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Obesity
Morbid Obesity
Keywords: sedentary
activity
morbid obesity
obesity
Actigraph
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2022-05-18
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to 1) evaluate the relationship of physical activity to quality of life and psychological functioning among adults with severe obesity (BMI\>40) and 2) evaluate the effects of activity monitoring on changes in physical activity during a 6-week intervention interval.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* BMI greater than or equal to 40
* Sit or lie down greater than or equal to 9 hours per day

Exclusion Criteria:

* Participating in regular exercise (any planned exercise)
* Participating in a formal weight loss or exercise program
* Planning to join a formal weight loss or exercise program in the next 2 months
* Cannot stand up without assistance
* Currently pregnant
* Planning to get pregnant in the next 2 months
* Given birth in past 9 months
* Currently breast feeding
* Weigh over 400 lbs
* Highest level of education is below 8th grade
* PHQ-9 score less than 15
* Visual impairment that impairs ability to read
* Any condition(s) that would make it challenging to follow instructions/directions
* Cognitive disorder (e.g., dementia)

Primary outcomes:
measure: Sedentary time
timeFrame: Change from baseline to 6 weeks
measure: Sit to stand transitions
timeFrame: Change from baseline to 6 weeks
measure: Self-report physical activity
timeFrame: Change from baseline to 6 weeks
measure: Physical function
timeFrame: Change from baseline to 6 weeks
measure: Health Related Quality of life
timeFrame: Change from baseline to 6 weeks
Secondary outcomes:
measure: Perceived stress
timeFrame: Change from baseline to 6 weeks
measure: Psychological distress
timeFrame: Change from baseline to 6 weeks
measure: Insomnia
timeFrame: Change from baseline to 6 weeks
measure: Sleep quality
timeFrame: Change from baseline to 6 weeks
measure: Pain perception measure 1
timeFrame: Change from baseline to 6 weeks
measure: Pain perception measure 2
timeFrame: Change from baseline to 6 weeks
measure: Weight Stigma measure 1
timeFrame: Change from baseline to 6 weeks
measure: Weight Stigma measure 2
timeFrame: Change from baseline to 6 weeks
measure: Weight Stigma measure 3
timeFrame: Change from baseline to 6 weeks
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
Study officials:
affiliation: Cardiopulmonary Behavioral Medicine at OSU
name: Charles Emery, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02278588: Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Official title: Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
First posted: 2014-10-30
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Idiopathic Parkinson's disease (IPD) and Healthy Controls (HC)

Brief summary: In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.


Eligibility criteria: IPD or HC subjects who were enrolled in a similar study about 2.5 years ago and for whom Baseline DTI data are available.

Primary outcomes:
measure: Change in cognitive biomarkers assessed by DTI
timeFrame: 2.5 years
measure: Comparison of change in cognitive biomarkers with change in MMSE and MoCA scores
timeFrame: 2.5 years
Secondary outcomes:
measure: Comparison of Baseline plasma BDNF with magnitude of change in brain cognitive biomarkers and MMSE and MoCA scores
timeFrame: 2.5 years
measure: Comparison of changes in plasma BDNF with changes in brain cognitive biomarkers and MMSE and MoCA scores
timeFrame: 2.5 years
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: University at Buffalo
state: New York
Study officials:
References:
Clinical trial NCT00558688: A Photodynamic Therapy for Treatment of Actinic Keratoses
Official title: A Photodynamic Therapy for Treatment of Actinic Keratoses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Actinic Keratoses
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2007-11-15
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs absence of treatment for actinic keratoses.

Detailed description: This study seeks to evaluate the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs. absence of treatment for actinic keratoses

Eligibility criteria: Inclusion Criteria:

Age greater than or equal to 18 years

* Have a t least 4 nonhypertrophic AK lesions on the body
* The subjects are in good health
* The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate to the investigator

Exclusion Criteria:

* Subjects who are pregnant or lactating
* Subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis
* Subjects with use of photosensitizing drugs within 1 week of study start
* Subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry
* Subjects with systemic steroid therapy within 4 weeks before study entry
* Subjects who received previous treatment of target AKs
* Subjects with systemic treatment with chemotherapeutic agents, masoprocol (Actinex), immunotherapy, or retinoids within 2 months of study entry
* Subjects with prior history of hypersensitivity reactions to lidocaine
* Subjects who are unable to understand the protocol or to give informed consent

Primary outcomes:
measure: Visual assessment of lesions
timeFrame: 4 weeks
Secondary outcomes:
measure: Patient subjective assessment and Safety
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University Department of Dermatology
state: Illinois
Study officials:
affiliation: Northwestern University
name: Murad Alam, MD
role: PRINCIPAL_INVESTIGATOR
References: